This mechanistic (Non-CTIMP) study will utilise a within-subjects design to examine a candidate brain biomarker of increased plasticity under Psilocybin. Up to 25mg of Psilocybin will be administered under standardised conditions on two occasions, separated by four weeks with in-dosing EEG recordings.~The primary end-point will take place 8 weeks from the first dosing session after which patients will be remotely monitored monthly for 6 months.
The purpose of this study is to assess brain activity under Psilocybin in a cohort of people with fibromyalgia.